Latest news
Investment in formulation development
Iconovo has raised 2.3 million EUR to expand the in-house development capacity. We will now be able to offer a comprehensive product development including…
Dry Powder Inhalers in London
Iconovo CEO Dr. Orest Lastow will be giving a speach at Dry Powder Inhalers Conference 27-28 July in London. The title of the speach is "How to develop…
Press releases
Dec 21, 2020, 07:30
News
IR
English
Regulatory
MAR
Corporate Information
Other Corporate Information
Dec 21, 2020, 07:30
News
IR
Swedish
Regulatory
MAR
Corporate Information
Other Corporate Information
Nov 26, 2020, 14:38
News
IR
Swedish
Corporate Information
Other Corporate Information
Nov 26, 2020, 14:38
News
IR
English
Corporate Information
Other Corporate Information
Nov 17, 2020, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Nov 17, 2020, 08:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Nomination Committee
Oct 28, 2020, 08:33
News
IR
English
Corporate Information
Other Corporate Information
Oct 27, 2020, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q3
Oct 19, 2020, 13:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Oct 19, 2020, 13:30
News
IR
English
Corporate Information
Other Corporate Information
Sep 30, 2020, 09:00
News
IR
English
Corporate Information
Presentation
Sep 30, 2020, 09:00
News
IR
Swedish
Corporate Information
Presentation
Sep 15, 2020, 11:00
News
IR
Swedish
Corporate Information
Other Corporate Information
Sep 02, 2020, 09:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 20, 2020, 13:51
News
IR
English
Corporate Information
Other Corporate Information
Aug 20, 2020, 08:30
News
IR
English
Corporate Information
Other Corporate Information
Aug 20, 2020, 08:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 19, 2020, 09:30
News
IR
English
Corporate Information
Other Corporate Information
Aug 19, 2020, 09:30
News
IR
Swedish
Corporate Information
Other Corporate Information
Aug 19, 2020, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q2
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se
Press releases
Follow us on Linkedin
